Member Info for The.Italian

https://hbw.pharmaintelligence.informa.com/health i think you have to be signed up
to access the article ,which I'm not ,but if anyone is and can outline it it would be good.

good find bignose. confirms its quite an achievement to get the switch. down to recordati i suppose.hopefully operations update this week as if its in the trade press now people are going to want a company update.

thanks for the clarification Odysseus.i now understand the point you are making. the phase 2 results do actually refer to effectiveness in relation mild and mild to moderate sufferers, but i accept the point that there appears to be an inconsistency between the phase 2 and phase 3 effects of what is now med 3000.iam not sure if this will make it more likely that the EMA will want additional trials but as I've always accepted that that was possible, even likely, it does not fundamentally alter my personal appraisal of the risks.that said it is a completely valid point and it will be interesting to see if any clarification can be obtained, although i suspect the chances of this are at best minuscule. as one of the other posters alludes to ,we never get access to the full data package so always very hard ,if not impossible, to evaluate. as always risk versus reward

in a way i agree with both IFOXXX and A1EX's posts.we do need an A lister ,but i can see the point about user retention.the main point for me is that they remind me of something i am in danger of forgetting. ihave got used to melody not charging for the concerts and that sort of feels the norm,so i tend to forget they will be charging for brixton. clearly the acts are going to have to be of sufficient quality and attraction to justify a charge. its going to be very interesting(and very important) to see who is in the line up

i should have said "i"never buy.not trying to give advice as such.

as I'm a new investor i can't comment on the historic spread as such but i can say that never buy when the spread id over 6% and usually i don't like to go over 4%,so current spread perfectly acceptable

odysseus thanks for your reply.i wonder if you can clarify which forest plots you have in mind as my strong recollection is that the positive results in december were certainly not limited to mild cases only.i cannot get onto the april presentation at the moment as it won't download for some reason,but just going off the general website narrative it states under results 'striking consistency being statistically superior to baseline for all three co-primary endpoints, as well as being statistically significant in each separate cohort of severity (mild,moderate and severe) ". the conclusion states that it will likely find use by the substantial number of patients,especially those with ED of a mild to moderate nature and patients who are contraindicated for use with existing products. imo it's hardly surprising that patients with severe ED are likely to benefit less and FUM are not claiming they would do so, but it does not seem to be limited in effect to the mildest form.i am no scientist and have no science background at all so i may have missed something and if you can point to the relevant statistical evidence to support your view i would be interested.

so presumably odysseus you won't now be investing.

bald eagle my reasons for topping up are personal based upon my own financial circumstance,risk profile and certain other things.not in anyway based on the posts of ananda, goldilocks or any other poster.thanks for your good wishes.

thanks 5Orrell.clearer now

sorry 5Orrell.i don't understand your post at all.can you elucidate please.

have topped up this morning .couldnt buy total in one go so had to split.looking tight to buy imo.

bald eagle all is forgiven.in these strange time we can all do with a good classical allusion.actually it's good news i suppose that the placebo showed similar strong effects previously, as i take it the the point he was making was that perhaps the recent results were somehow anomalous, or at least not supported by previous results. glad to hear that is not the case.

so no obvious reason for Friday's rise. today will be interesting

https://www.lachmanconsultants.com/2020/02/when-it-rains-it-pours-recent-rx-to-otc-switches/ doesn't look as though this type of switch is that easy. this is usa based, but no switches for 3 years may put regent's achievement in context. just musing as its obviously a specialist area of knowledge, so just gnawing at the edges. interesting though imo

not sure how much relevance this will have in practice, but for those with time on their hands perhaps have a look at this. the marketing section(para 19 onwards )outlines the sort of advertising content and approaches which are not allowed etc,but it seems mostly the sensible precautionary stuff one would expect https://uk.practicallaw.thomsonreuters.com/2-618-6661?transitionType=Default&contextData=(sc.Default)&firstPage=true&bhcp=1#co_anchor_a477470

i have zero knowledge of the current music scene so probably shouldn't comment,but i do wonder if it's a genre thing. i know posters will say nelly is incredibly popular etc, but personally I'm hoping for a much wider range of artists than we have seen for the most part to date (with some notable exceptions,i do expect this from brixton when announced so await the details with interest.

oh volatility thank god for the correction i was just on the point of posting to say i didn't realise barder had an interest in sng. probably a good thing he hasn't, as if he hd he would probably not be focussed on FUM !. on a serious note it is a good thing he has an interest. one of the constant criticisms on MTFB was that the board held no shares at all.it was all explained away ostensibly plausibly as being an american style company and that was how they did things in US. nonesense of course,so good to know they have at least some skin in the game here.

yes thats my take as well Volatility.also on the point re viagra and generic market competitors, if we get OTC approval we will presumably be able to highlight the apparent advantages of MED 3000 over the others (e.g. speed of onset)and in this connection i have been looking at the lloyds pharmacy website for viagra and sildenafil and it states that both should be taken on an empty stomach.i did not know this, so presumably candlelight suppers are out for those users. another (perhaps very small) point of differentiation.

that is certainly the hope.fingers crossed!